Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04874480 · ClinicalTrials.gov registry record · Phase 1
Tegavivint for the Treatment of Relapsed or Refractory Leukemia
A Phase 1 study of Refractory Leukemia and Recurrent Leukemia, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT04874480 is a Phase 1 study of Refractory Leukemia and Recurrent Leukemia that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 9 participants, below the 40-participant average among 3 other Refractory Leukemia trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04874480, a Phase 1 study of Refractory Leukemia and Recurrent Leukemia, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial is to find out the best dose and side effects of tegavivint in treating patients with leukemia that has come back (relapsed) or does not response to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint in combination with decitabine may help control the disease.
Conditions Studied
Interventions
- DRUG Decitabine
- DRUG Tegavivint
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-09-27 |
| Est. Completion | 2027-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04874480
The ClinicalTrials.gov registry entry for NCT04874480 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 40-participant average among 3 other Refractory Leukemia trials with a reported enrollment target (77% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractory Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Decitabine is the first listed.
NCT04874480 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04874480 about?
NCT04874480 is a clinical study titled "Tegavivint for the Treatment of Relapsed or Refractory Leukemia". This phase I trial is to find out the best dose and side effects of tegavivint in treating patients with leukemia that has come back (relapsed) or does not response to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Givin...
What is the current status of trial NCT04874480?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2021-09-27. Estimated completion is 2027-02-02.
What conditions does trial NCT04874480 study?
This clinical trial studies the following conditions: Refractory Leukemia, Recurrent Leukemia.
What interventions are being tested in trial NCT04874480?
The interventions under investigation include: Decitabine (DRUG), Tegavivint (DRUG).
Who is sponsoring clinical trial NCT04874480?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04874480 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Study of Revumenib and Mezigdomide in People With Leukemia
RECRUITING · Phase 1
-
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.